Renal safety of sunitinib treatment: A prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Billemont, B. [1 ]
Rixe, O. [2 ]
Meric, J. B. [3 ]
Alexandre, J. [1 ]
Goldwasser, F. [1 ]
Izzedine, H. [2 ]
机构：
[1] Cochin Hosp, AP HP, Paris, France
[2] Hop La Pitie Salpetriere, AP HP, Paris, France
[3] Bligny Hosp, Briis Sous Forges, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [1] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [3] A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).
    Hutson, T. E.
    Bukowski, R. M.
    Rini, B. I.
    Gore, M. E.
    Larkin, J. M. G.
    Figlin, R. A.
    Barrios, C. H.
    Escudier, B.
    Lin, X.
    Fly, K. D.
    Martell, B.
    Matczak, E.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Side effects of sunitinib malate (SM) treatment for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Carteni, G. G.
    Montano, M.
    Perrotta, E.
    Otero, M.
    Guida, T.
    Ragone, G.
    Aurilio, G.
    Maiorino, L.
    Stavolo, C.
    Panza, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [6] A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Uemura, H.
    Shinohara, N.
    Naito, S.
    Akaza, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Cella, David
    Davis, Mellar P.
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Hahn, Elizabeth A.
    Korytowsky, Beata
    Bhattacharyya, Helen
    Sandin, Rickard
    Beaumont, Jennifer L.
    Matczak, Ewa
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] External validation of a sunitinib prognostic nomogram in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Yu, Changhong
    Kattan, Michael W.
    Hutson, Thomas E.
    Hudes, Gary R.
    Yuan, Jinyu
    Valota, Olga
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
  • [10] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345